Latest News and Press Releases
Want to stay updated on the latest news?
-
Previously approved reverse stock split to be implemented on Friday, October 6, 2017 REDWOOD CITY, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a...
-
REDWOOD CITY, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
-
Updated Data Highlighted in Poster Presentation at 10th International Meeting of Pediatric Endocrinology Phase III Study Expected to Begin by End of 2017 REDWOOD CITY, Calif., Sept. 15, 2017 ...
-
Protection of Associated Claims into 2035 REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing...
-
David O’Toole to Depart Company; Interim CFO Appointed and Search for New CFO Initiated REDWOOD CITY, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a...
-
Completed Successful FDA Meeting for DCCR in Prader-Willi SyndromePreparing to begin Phase III program by the end of the yearMonetized Non-Strategic Assets Through Sale of NeoForce, Inc. Subsidiary ...
-
REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
-
Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome
Positive guidance received on key elements of Phase III programCompany expects to initiate pivotal Phase III clinical trial by year-end 2017DCCR has orphan designation for the treatment of PWS in the...
-
Completed merger with Essentialis, Inc. and concurrent financing of $10 millionNew company name, Soleno Therapeutics, Inc., to reflect new strategic focus on rare disease therapeutics; stock to trade...
-
REDWOOD CITY, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today...